Consensus of the Brazilian Headache Society (SBCe) for the Prophylactic Treatment of Episodic Migraine: part I

Abstract

The Brazilian Headache Society (Sociedade Brasileira de Cefaleia, SBCe, in Portuguese) nominated a Committee of Authors with the aim of establishing a consensus with recommendations regarding prophylactic treatment for episodic migraine based on articles published in the worldwide literature, as well as personal experience. Migraine affects 1 billion people around the world and more than 30 million Brazilians. In addition, it is an underdiagnosed and undertreated disorder. It is well known within the medical community of neurologists, and especially among headache specialists, that there is a need to disseminate knowledge about prophylactic treatment for migraine. For this purpose, together with the need for drug updates and to expand knowledge of the disease itself (frequency, intensity, duration, impact and perhaps the progression of migraine), this Consensus was developed, following a full online methodology, by 12 groups who reviewed and wrote about the pharmacological categories of the drugs used and, at the end of the process, met to read and establish conclusions for this document. The drug classes studied were: anticonvulsants, tricyclic antidepressants, monoclonal anti-calcitonin gene-related peptide (anti-CGRP) antibodies, beta-blockers, antihypertensives, calcium channel inhibitors, other antidepressants (selective serotonin reuptake inhibitors, SSRIs, and dual-action antidepressants), other drugs, and polytherapy. Hormonal treatment and anti-inflammatories and triptans in minimum prophylaxis schemes (miniprophylaxis) will be covered in a specific chapter. The drug classes studied for part I of the Consensus were: anticonvulsants, tricyclic antidepressants, monoclonal anti-CGRP antibodies, and beta-blockers.

Resumo

A Sociedade Brasileira de Cefaleia (SBCe) nomeou um Comitê de Autores com o objetivo de estabelecer um consenso com recomendações sobre o tratamento profilático da enxaqueca episódica com base em artigos da literatura mundial e da experiência pessoal. A enxaqueca é um distúrbio subdiagnosticado e subtratado que acomete um bilhão de pessoas no mundo e mais de 30 milhões de brasileiros. É conhecido na comunidade médica de neurologistas e, sobretudo, dos especialistas em cefaleia, a necessidade de se divulgar o conhecimento sobre o tratamento profilático da enxaqueca. Com esta finalidade, aliada às necessidades de atualizações de drogas e de se aumentar o conhecimento sobre a doença em si (frequência, intensidade, duração, impacto e talvez a progressão da enxaqueca), foi elaborado este Consenso, com metodologia totalmente on-line, por 12 grupos que revisaram e escreveram sobre as categorias farmacológicas das drogas e, ao final, reuniram-se para a leitura e conclusão do documento. As classes de drogas estudadas para este Consenso foram: anticonvulsivantes, antidepressivos tricíclicos, anticorpos monoclonais do antipeptídeo relacionado ao gene da calcitonina (peptídeo relacionado ao gene da calcitonina — anti-CGRP), betabloqueadores, anti-hipertensivos, inibidores dos canais de cálcio, outros antidepressivos (inibidores seletivos de recaptação de serotonina, ISRSs, e antidepressivos de ação dual), outras drogas, e politerapia. O tratamento hormonal, bem como anti-inflamatórios e triptanas em esquema de profilaxia mínima (miniprofilaxia), será abordado em um capítulo próprio. As classes de drogas estudadas na parte I do Consenso foram: anticonvulsivantes, antidepressivos tricíclicos, anticorpos monoclonais anti-CGRP, e betabloqueadores.

Keywords

Migraine Disorders - Consensus - Preventive Medicine

Palavras-chave

Transtornos de Enxaqueca - Consenso - Medicina Preventiva.

Authors' contributions:

EMM, PAK: discussion, group coordination, writing, review, conceptualization, editing, data collection; PSFS: discussion, group coordination, writing, review, conceptualization; AOK, ATNMC, CAPR, EMS, GOMT, IF, LCC, LMB, MFPP, PMP, PFMF: writing, review, discussion, conceptualization; EJP, JJFC, HCC: writing, review, editing, group coordination, discussion; JAS, LPQ, MNPS: writing, review, editing, discussion; JAMJ, MENMC: writing, review, discussion; JBAS: writing, discussion; JGS: writing; MRCFF, MEJ, YDF: writing, review; PASRF: conceptualization, data collection, writing, review, editing.

Publikationsverlauf

Eingereicht: 11. Dezember 2021

Angenommen: 24. Mai 2022

Artikel online veröffentlicht:
17. Oktober 2022

• References

• 1 Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition. Cephalalgia 2018; 38 (01) 1-211 . PMID: 29368949 PubMed
• 2 Kowacs F., Roesler C.A. D. P., Piovesan É.J., Sarmento E.M., Campos H.C. D., Maciel Jr. J.A., Calia L.C., Barea L.M., Ciciarelli M.C., Valença M.M., Costa M.E. N. D. M., Peres M.F. P., Kowacs P.A., Rocha-Filho P.A. S., Silva-Néto R.P. D., Villa T.R., Jurno M.E.. (2019). Consenso da Sociedade Brasileira de Cefaleia sobre o tratamento da migrânea crônica [Consensus of the Brazilian Headache Society on the treatment of chronic migraine]. Arquivos de Neuro-Psiquiatria 77 (07) 509-520 https://doi.org/10.1590/0004-282x20190078
• 3 Silberstein S, Loder E, Diamond S, Reed ML, Bigal ME, Lipton RB. AMPP Advisory Group. Probable migraine in the United States: results of the American Migraine Prevalence and Prevention (AMPP) study. Cephalalgia 2007; 27 (03) 220-229 . PMID: 17263769
• 4 Queiroz LP, Peres MF, Piovesan EJ. et al. A nationwide population-based study of migraine in Brazil. Cephalalgia 2009; 29 (06) 642-649
• 5 Diamond S, Bigal ME, Silberstein S, Loder E, Reed M, Lipton RB. Patterns of diagnosis and acute and preventive treatment for migraine in the United States: results from the American Migraine Prevalence and Prevention study. Headache 2007; 47 (03) 355-363 Erratum in: Headache. 2007; 47(9):1365. PMID: 17371352
• 6 GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 2017 Sep 16;390(10100):1211-1259. doi: 10.1016/S0140-6736(17)32154-2. Erratum in: Lancet. 2017 Oct 28;390(10106):e38. PMID: 28919117; PMCID: PMC5605509
• 7 Steiner TJ, Stovner LJ, Vos T, Jensen R, Katsarava Z. Migraine is first cause of disability in under 50s: will health politicians now take notice?. J Headache Pain 2018; 19 (01) 17
• 8 Chan KY, Vermeersch S, de Hoon J, Villalón CM, Maassenvandenbrink A. Potential mechanisms of prospective antimigraine drugs: a focus on vascular (side) effects. Pharmacol Ther 2011; 129 (03) 332-351 . Epub 2010 Dec 2. PMID: 21130807
• 9 Comitê AD Hoc da Sociedade Brasileira de Cefaléia. Brazilian Headache Society (Filiada à International Headache Society). RECOMENDAÇÕES PARA O TRATAMENTO PROFILÁTICO DA MIGRÂNEA Consenso da Sociedade Brasileira de Cefaléia. Arq Neuropsiquiatr 2002; 60 (01) 159-169
• 10 Appendix C: AAN Classification of Evidence for the Rating of a Therapeutic Study. Continuum (Minneap Minn) 2015;21(4 Headache):1169. Doi: 10.1212/01.CON.0000470920.20859.fe. PMID: 26252602
• 11 Danesh A, Gottschalk PCH. Beta-blockers for migraine prevention: a review article. Curr Treat Options Neurol 2019; 21 (04) 20
• 12 Ramadan NM. Prophylactic migraine therapy: mechanisms and evidence. Curr Pain Headache Rep 2004; 8 (02) 91-95
• 13 Tfelt-Hansen P, Ågesen FN, Pavbro A, Tfelt-Hansen J. Pharmacokinetic Variability of Drugs Used for Prophylactic Treatment of Migraine. CNS Drugs 2017; May; 31 (05) 389-403
• 14 Min JH, Kwon HM, Nam H. The effect of propranolol on cerebrovascular reactivity to visual stimulation in migraine. J Neurol Sci 2011; 305 (1-2): 136-138
• 15 Jackson JL, Kuriyama A, Kuwatsuka Y. et al. Beta-blockers for the prevention of headache in adults, a systematic review and meta-analysis. PLoS One 2019; 14 (03) e0212785
• 16 Palferman TG, Gibberd FB, Simmonds JP. Prophylactic propranolol in the treatment of headache. Br J Clin Pract 1983; 37 (01) 28-29
• 17 Ahuja GK, Verma AK. Propranolol in prophylaxis of migraine. Indian J Med Res 1985; 82: 263-265
• 18 Kuritzky A, Hering R. Prophylactic treatment of migraine with long acting propranolol - a comparison with placebo. Cephalalgia 1987; 7 (6, suppl) 457-458
• 19 Silberstein SD, Holland S, Freitag F, Dodick DW, Argoff C, Ashman E. Evidence-based guideline update: Pharmacologic treatment for episodic migraine prevention in adults: Table 1. Neurology 2012; 78 (17) 1337-1345
• 20 Jensen R, Brinck T, Olesen J. Sodium valproate has a prophylactic effect in migraine without aura: a triple-blind, placebo-controlled crossover study. Neurology 1994; 44 (04) 647-651
• 21 Ashtari F, Shaygannejad V, Akbari M. A double-blind, randomized trial of low-dose topiramate vs propranolol in migraine prophylaxis. Acta Neurol Scand 2008; 118 (05) 301-305
• 22 Diener HC, Tfelt-Hansen P, Dahlöf C. et al; MIGR-003 Study Group. Topiramate in migraine prophylaxis–results from a placebo-controlled trial with propranolol as an active control. J Neurol 2004; 251 (08) 943-950
• 23 Fumagalli C, Maurizi N, Marchionni N, Fornasari D. β-blockers: Their new life from hypertension to cancer and migraine. Pharmacol Res 2020; 151: 104587
• 24 Barbanti P, Aurilia C, Egeo G, Fofi L. Migraine prophylaxis: what is new and what we need?. Neurol Sci 2011; 32 (Suppl. 01) S111-S115
• 25 Andersson PG, Dahl S, Hansen JH. et al. Prophylactic treatment of classical and non-classical migraine with metoprolol–a comparison with placebo. Cephalalgia 1983; 3 (04) 207-212
• 26 Kangasniemi P, Andersen AR, Andersson PG. et al. Classic migraine: effective prophylaxis with metoprolol. Cephalalgia 1987; 7 (04) 231-238 . PMID: 3322569
• 27 Steiner TJ, Joseph R, Hedman C, Rose FC. Metoprolol in the prophylaxis of migraine: parallel-groups comparison with placebo and dose-ranging follow-up. Headache 1988; 28 (01) 15-23
• 28 Siniatchkin M, Andrasik F, Kropp P. et al. Central mechanisms of controlled-release metoprolol in migraine: a double-blind, placebo-controlled study. Cephalalgia 2007; 27 (09) 1024-1032
• 29 Langohr HD, Gerber WD, Koletzki E, Mayer K, Schroth G. Clomipramine and metoprolol in migraine prophylaxis–a double-blind crossover study. Headache 1985; 25 (02) 107-113 . PMID: 3886599
• 30 Kangasniemi P, Hedman C. Metoprolol and propranolol in the prophylactic treatment of classical and common migraine. A double-blind study. Cephalalgia 1984; 4 (02) 91-96
• 31 Stellar S, Ahrens SP, Meibohm AR, Reines SA. Migraine prevention with timolol. A double-blind crossover study. JAMA 1984; 252 (18) 2576-2580
• 32 Tfelt-Hansen P, Standnes B, Kangasneimi P, Hakkarainen H, Olesen J. Timolol vs propranolol vs placebo in common migraine prophylaxis: a double-blind multicenter trial. Acta Neurol Scand 1984; 69 (01) 1-8 . PMID: 6367336
• 33 Forssman B, Lindblad CJ, Zbornikova V. Atenolol for migraine prophylaxis. Headache 1983; 23 (04) 188-190
• 34 Johannsson V, Nilsson LR, Widelius T. et al. Atenolol in migraine prophylaxis a double-blind cross-over multicentre study. Headache 1987; 27 (07) 372-374
• 35 Stensrud P, Sjaastad O. Comparative trial of Tenormin (atenolol) and Inderal (propranolol) in migraine. Ups J Med Sci Suppl 1980; 31: 37-40
• 36 Sudilovsky A, Elkind AH, Ryan Sr RE, Saper JR, Stern MA, Meyer JH. Comparative efficacy of nadolol and propranolol in the management of migraine. Headache 1987; 27 (08) 421-426
• 37 Zanchetti A. Clinical pharmacodynamics of nebivolol: new evidence of nitric oxide-mediated vasodilating activity and peculiar haemodynamic properties in hypertensive patients. Blood Press Suppl 2004; 1: 17-32
• 38 Pessina AC. Metabolic effects and safety profile of nebivolol. J Cardiovasc Pharmacol 2001; 38 (Suppl. 03) S33-S35
• 39 Schellenberg R, Lichtenthal A, Wöhling H, Graf C, Brixius K. Nebivolol and metoprolol for treating migraine: an advance on beta-blocker treatment?. Headache 2008; 48 (01) 118-125
• 40 Ekbom K, Lundberg PO. Clinical trial of LB-46 (d, 1-4-(2-hydroxy-3-isopropylaminopropoxy)indol. An adrenergic beta-receptor blocking agent in migraine prophylaxis. Headache 1972; 12 (01) 15-17
• 41 Sjaastad O, Stensrud P. Clinical trial of a beta-receptor blocking agent (LB 46) in migraine prophylaxis. Acta Neurol Scand 1972; 48 (01) 124-128
• 42 Perucca E. A pharmacological and clinical review on topiramate, a new antiepileptic drug. Pharmacol Res 1997; 35 (04) 241-256
• 43 Silberstein SD, Neto W, Schmitt J, Jacobs D. MIGR-001 Study Group. Topiramate in migraine prevention: results of a large controlled trial. Arch Neurol 2004; 61 (04) 490-495
• 44 Brandes JL, Saper JR, Diamond M. et al; MIGR-002 Study Group. Topiramate for migraine prevention: a randomized controlled trial. JAMA 2004; 291 (08) 965-973
• 45 Diamond M, Dahlöf C, Papadopoulos G, Neto W, Wu SC. Topiramate improves health-related quality of life when used to prevent migraine. Headache 2005; 45 (08) 1023-1030
• 46 Simon D, Penry JK. Sodium di-N-propylacetate (DPA) in the treatment of epilepsy. A review. Epilepsia 1975; 16 (04) 549-573
• 47 Sørensen KV. Valproate: a new drug in migraine prophylaxis. Acta Neurol Scand 1988; 78 (04) 346-348 . PMID: 3146862
• 48 Cutrer FM, Limmroth V, Moskowitz MA. Possible mechanisms of valproate in migraine prophylaxis. Cephalalgia 1997; 17 (02) 93-100
• 49 Linde M, Mulleners WM, Chronicle EP, McCrory DC. Valproate (valproic acid or sodium valproate or a combination of the two) for the prophylaxis of episodic migraine in adults. Cochrane Database Syst Rev 2013; (06) CD010611
• 50 Hering R, Kuritzky A. Sodium valproate in the prophylactic treatment of migraine: a double-blind study versus placebo. Cephalalgia 1992; 12 (02) 81-84
• 51 Mathew NT, Saper JR, Silberstein SD. et al. Migraine prophylaxis with divalproex. Arch Neurol 1995; 52 (03) 281-286 . PMID: 7872882
• 52 Silberstein SD, Collins SD. Long-term Safety of Depakote in Headache Prophylaxis Study Group. Safety of divalproex sodium in migraine prophylaxis: an open-label, long-term study. Headache 1999; 39 (09) 633-643
• 53 Beattie K, Phadke G, Novakovic J. Lamotrigine. In: Britton HG. ed. Profiles Drug Subst Excip Relat Methodol. 2012. 37. 245-85 . Epub 2012 Mar 19. PMID: 22469320.
• 54 Steiner TJ, Findley LJ, Yuen AW. Lamotrigine versus placebo in the prophylaxis of migraine with and without aura. Cephalalgia 1997; 17 (02) 109-112
• 55 Gupta P, Singh S, Goyal V, Shukla G, Behari M. Low-dose topiramate versus lamotrigine in migraine prophylaxis (the Lotolamp study). Headache 2007; 47 (03) 402-412
• 56 Lampl C, Buzath A, Klinger D, Neumann K. Lamotrigine in the prophylactic treatment of migraine aura–a pilot study. Cephalalgia 1999; 19 (01) 58-63
• 57 D'Andrea G, Granella F, Cadaldini M, Manzoni GC. Effectiveness of lamotrigine in the prophylaxis of migraine with aura: an open pilot study. Cephalalgia 1999; 19 (01) 64-66
• 58 Lampl C, Katsarava Z, Diener HC, Limmroth V. Lamotrigine reduces migraine aura and migraine attacks in patients with migraine with aura. J Neurol Neurosurg Psychiatry 2005; 76 (12) 1730-1732 . PMID:1629190
• 59 Pascual J, Caminero AB, Mateos V. et al. Preventing disturbing migraine aura with lamotrigine: an open study. Headache 2004; 44 (10) 1024-1028 . PMID:15546267
• 60 Chen WT, Fuh JL, Lu SR, Wang SJ. Persistent migrainous visual phenomena might be responsive to lamotrigine. Headache 2001; 41 (08) 823-825
• 61 Kumar A, Maini K, Kadian R. Levetiracetam. 2020. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan. PMID: 29763065.
• 62 Patsalos PN. The pharmacokinetic characteristics of levetiracetam. Methods Find Exp Clin Pharmacol 2003; 25 (02) 123-129 . PMID:12731458
• 63 Lyseng-Williamson KA. Levetiracetam: a review of its use in epilepsy. Drugs 2011; 71 (04) 489-514
• 64 de Tommaso M, Guido M, Sardaro M. et al. Effects of topiramate and levetiracetam vs placebo on habituation of contingent negative variation in migraine patients. Neurosci Lett 2008; 442 (02) 81-85
• 65 Verma A, Srivastava D, Kumar A, Singh V. Levetiracetam in migraine prophylaxis: a randomized placebo-controlled study in a rural medical institute in northern India. Clin Neuropharmacol 2013; 36 (06) 193-197
• 66 Gallai V, Alberti A, Rossi C, Coppola F, Gallai B, Mazzotta G, Sarchielli P. An open-label pilot study on the efficacy and tolerability of levetiracetam in the prophylaxis of migraine. The Journal of Headache and Pain 2003; 4 (02) 92-96
• 67 Pizza V, Busillo V, Agresta A, Bisogno A, Capasso A. Elderly Patients with Migraine: An Open-Label Study on Prophylaxis Therapy with Levetiracetam. Central Nervous System Agents in Medicinal Chemistry 2011; 11 (01) 31-34
• 68 Brighina F, Palermo A, Aloisio A, Francolini M, Giglia G, Fierro B. Levetiracetam in the prophylaxis of migraine with aura: a 6-month open-label study. Clin Neuropharmacol 2006; 29 (06) 338-342 . PMID: 17095897
• 69 Silberstein S, Goode-Sellers S, Twomey C, Saiers J, Ascher J. Randomized, double-blind, placebo-controlled, phase II trial of gabapentin enacarbil for migraine prophylaxis. Cephalalgia 2013; 33 (02) 101-111
• 70 Mathew NT, Rapoport A, Saper J, Magnus L, Klapper J, Ramadan N, Stacey B, Tepper S. Efficacy of gabapentin in migraine prophylaxis. Headache 2001 Feb;41(2):119–28. doi: 10.1046/j.1526-4610.2001.111006119.x. PMID: 11251695
• 71 Zain S, Khan M, Alam R, Zafar I, Ahmed S. Comparison of efficacy and safety of topiramate with gabapentin in migraine prophylaxis: randomized open label control trial. J Pak Med Assoc 2013; 63 (01) 3-7
• 72 Jiménez-Hernández MD, Torrecillas Nárvaez MD, Friera Acebal G. Eficacia y seguridad de la gabapentina en el tratamiento preventivo de la migraña. [Effectiveness and safety of gabapentin in the preventive treatment of migraine] Rev Neurol 2002; 35 (07) 603-606
• 73 Hesami O, Shams MR, Ayazkhoo L. et al. Comparison of pregabalin and sodium valproate in migraine prophylaxis: a randomized double-blinded study. Iran J Pharm Res 2018; 17 (02) 783-789
• 74 Pizzolato R, Villani V, Prosperini L, Ciuffoli A, Sette G. Efficacy and tolerability of pregabalin as preventive treatment for migraine: a 3-month follow-up study. J Headache Pain 2011; 12 (05) 521-525
• 75 Alrashood ST. Carbamazepine. Profiles Drug Subst Excip Relat Methodol 2016; 41: 133-321
• 76 Rompel H, Bauermeister PW. Aetiology of migraine and prevention with carbamazepine (Tegretol): results of a double-blind, cross-over study. S Afr Med J 1970; 44 (04) 75-80
• 77 Mulleners WM, McCrory DC, Linde M. Antiepileptics in migraine prophylaxis: an updated Cochrane review. Cephalalgia 2015; 35 (01) 51-62
• 78 Preuss CV, Randhawa G, Wy TJP, Saadabadi A. Oxcarbazepine. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021. . PMID: 29493938.
• 79 Silberstein S, Saper J, Berenson F, Somogyi M, McCague K, D'Souza J. Oxcarbazepine in migraine headache: a double-blind, randomized, placebo-controlled study. Neurology 2008; 70 (07) 548-555
• 80 Wheless JW, Ramsay RE, Collins SD. Vigabatrin. Neurotherapeutics 2007; 4 (01) 163-172
• 81 Ghose K, Niven BE, Berry D. A double-blind crossover comparison of the effects of vigabatrin with placebo in the prevention of migraine headache. J Headache Pain 2002; 3 (02) 79-85 PubMed
• 82 Griffin III CE, Kaye AM, Bueno FR, Kaye AD. Benzodiazepine pharmacology and central nervous system-mediated effects. Ochsner J 2013; 13 (02) 214-223
• 83 Stensrud P, Sjaastad O. Clonazepam (rivotril) in migraine prophylaxis. Headache 1979; 19 (06) 333-334
• 84 Maizels M. Clonazepam for refractory headache: three cases illustrative of benefit and risk. Headache 2010; 50 (04) 650-656
• 85 Kadian R, Kumar A. Zonisamide. [Updated 2019 Oct 21]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020
• 86 Mohammadianinejad SE, Abbasi V, Sajedi SA. et al. Zonisamide versus topiramate in migraine prophylaxis: a double-blind randomized clinical trial. Clin Neuropharmacol 2011; 34 (04) 174-177 . PMID:21738025
• 87 Assarzadegan F, Tabesh H, Hosseini-Zijoud SM, Beale AD, Shoghli A, Ghafoori YazdiM, Mansouri B, Hesami O, Beladi MoghadamN, Delavar KasmaeiH. Comparing Zonisamide With Sodium Valproate in the Management of Migraine Headaches: Double-Blind Randomized Clinical Trial of Efficacy and Safety. Iran Red Crescent Med J 2016 Apr 30;18(9):e23768. doi: 10.5812/ircmj.23768. PMID: 28144450; PMCID: PMC5253208
• 88 Villani V, Ciuffoli A, Prosperini L, Sette G. Zonisamide for migraine prophylaxis in topiramate-intolerant patients: an observational study. Headache 2011; 51 (02) 287-291
• 89 Drake Jr ME, Greathouse NI, Renner JB, Armentbright AD. Open-label zonisamide for refractory migraine. Clin Neuropharmacol 2004; 27 (06) 278-280
• 90 Chung JY, Kim MW, Kim M. Efficacy of zonisamide in migraineurs with nonresponse to topiramate. BioMed Res Int 2014; 2014: 891348
• 91 Moreno RA, Moreno DH, Soares MB. Psicofarmacologia de antidepressivos. Rev Bras Psiquiatr 1999; 21 (Suppl. 01) 24-40 https://doi.org/10.1590/S1516-44461999000500006
• 92 Burch R. Antidepressants for Preventive Treatment of Migraine. Curr Treat Options Neurol 2019 Mar 21;21(4):18. doi: 10.1007/s11940-019-0557-2. PMID: 30895388
• 93 Couch JR. Amitriptyline Versus Placebo Study Group. Amitriptyline in the prophylactic treatment of migraine and chronic daily headache. Headache 2011; 51 (01) 33-51
• 94 Dodick DW, Freitag F, Banks J. et al; CAPSS-277 Investigator Group. Topiramate versus amitriptyline in migraine prevention: a 26-week, multicenter, randomized, double-blind, double-dummy, parallel-group noninferiority trial in adult migraineurs. Clin Ther 2009; 31 (03) 542-559
• 95 Gonçalves AL, Martini Ferreira A, Ribeiro RT, Zukerman E, Cipolla-Neto J, Peres MF. Randomised clinical trial comparing melatonin 3 mg, amitriptyline 25 mg and placebo for migraine prevention. J Neurol Neurosurg Psychiatry 2016; 87 (10) 1127-1132
• 96 Noone JF. Clomipramine in the prevention of migraine. J Int Med Res 1980; 8 (Suppl. 03) 49-52
• 97 Domingues RB, Silva ALP, Domingues SA, Aquino CCH, Kuster GW. A double-blind randomized controlled trial of low doses of propranolol, nortriptyline, and the combination of propranolol and nortriptyline for the preventive treatment of migraine. Arq Neuropsiquiatr 2009; 67 (04) 973-977
• 98 Paemeleire K, Maassen Van Den Brink A. Calcitonin-gene-related peptide pathway mAbs and migraine prevention. Current Opinion in Neurology 2018; 1
• 99 Walter S, Bigal ME. TEV-48125: a Review of a Monoclonal CGRP Antibody in Development for the Preventive Treatment of Migraine. Current Pain and Headache Reports 2015; 19 (03) 6-12
• 100 Edvinsson L, Haanes KA, Warfvinge K, Krause DN. CGRP as the target of new migraine therapies - successful translation from bench to clinic. Nat Rev Neurol 2018; 14 (06) 338-350
• 101 Goadsby PJ, Reuter U, Hallström Y. et al. A controlled trial of erenumab for episodic migraine. N Engl J Med 2017; 377 (22) 2123-2132
• 102 Dodick DW, Ashina M, Brandes JL. et al. ARISE: A Phase 3 randomized trial of erenumab for episodic migraine. Cephalalgia 2018; 38 (06) 1026-1037
• 103 Stauffer VL, Dodick DW, Zhang Q, Carter JN, Ailani J, Conley RR. Evaluation of galcanezumab for the prevention of episodic migraine: The EVOLVE-1 randomized clinical trial. JAMA Neurol 2018; 75 (09) 1080-1088
• 104 Skljarevski V, Matharu M, Millen BA, Ossipov MH, Kim BK, Yang JY. Efficacy and safety of galcanezumab for the prevention of episodic migraine: Results of the EVOLVE-2 Phase 3 randomized controlled clinical trial. Cephalalgia 2018; 38 (08) 1442-1454
• 105 Dodick DW, Silberstein SD, Bigal ME. et al. Effect of fremanezumab compared with placebo for prevention of episodic migraine: a randomized clinical trial. JAMA 2018; 319 (19) 1999-2008
• 106 Ferrari MD, Diener HC, Ning X. et al. Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial. Lancet 2019;394(10203):1030–1040. Doi: 10.1016/S0140-6736(19)31946-4 Erratum in: Lancet. 2019 Oct 29; PMID: 31427046
• 107 Dodick DW, Goadsby PJ, Silberstein SD. et al; ALD403 study investigators. Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial. Lancet Neurol 2014; 13 (11) 1100-1107
• 108 Ashina M, Saper J, Cady R. et al. Eptinezumab in episodic migraine: A randomized, double-blind, placebo-controlled study (PROMISE-1). Cephalalgia 2020; 40 (03) 241-254
• 109 Dodick DW, Gottschalk C, Cady R, Hirman J, Smith J, Snapinn S. Eptinezumab demonstrated efficacy in sustained prevention of episodic and chronic migraine beginning on day 1 after dosing. Headache 2020; 60 (10) 2220-2231